



February 26, 2026

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans".

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl.: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

info@lupin.com | www.lupin.com



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans

Naples, Fla, Mumbai, India, FEBRUARY 26, 2026: Global pharmaceutical leader, Lupin Limited (Lupin), today announced that CEO Vinita Gupta was recognized on the [CNBC Changemakers list of Women Transforming Business](#). Each year, this prestigious list honors female leaders who are redefining industries, breaking barriers, and driving lasting change across various business sectors.

“I am honored to be recognized as a CNBC Changemaker and listed amongst such extraordinary leaders who are driving significant change and impact,” said Vinita Gupta, CEO, Lupin. “This recognition reflects not only my own journey, but the shared dedication of everyone at Lupin who works each day to help transform hope into healing. I truly believe that meaningful change occurs when purpose is matched by execution. I extend my congratulations to all the other honorees.”

Vinita built Lupin’s U.S. business from the ground up. During her tenure as CEO, the company grew into the third-largest generic medicine supplier to the U.S. and the world’s seventh-largest pharmaceutical company by volume. Under her leadership, Lupin continues to expand its impact on affordable medicine, complex generics, inhalation and biosimilars. In late 2025, Lupin gained FDA approval for its first biosimilar Pegfilgrastim, marking a pivotal step in Lupin’s ongoing commitment to providing high-quality, affordable medicines to U.S. patients.

Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy. In 2025, she advanced efforts to strengthen domestic pharmaceutical manufacturing by progressing Lupin’s reshoring initiative and announcing plans for a new state-of-the-art inhalation facility in Coral Springs, Florida. The site is anticipated to produce multiple respiratory products, including Albuterol. By expanding production in the United States, Lupin is reinforcing medicine security and improving patient access to critical medicines.

CNBC Changemakers is an annual list spotlighting women whose accomplishments have left an indelible mark on the business world. The list recognizes female leaders who are finding solutions, driving innovation, and building businesses poised for sustainable success.

Those recognized in the CNBC Changemakers list will be honored at the CNBC Changemakers Summit on April 16th in New York.

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

For further information or queries, please contact

Elise Titan

Director – U.S. Communications, Lupin

elisetitan@lupin.com